RhumbLine Advisers
DRUG icon

RhumbLine Advisers’s Bright Minds Biosciences DRUG Stock Holding History

RhumbLine Advisers’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$448K Buy
9,001
+268
+3% +$18.9K ﹤0.01% 2801
2026
Q2 		$613K Buy
8,733
+971
+13% +$76.2K ﹤0.01% 2628
2026
Q1 		$566K Buy
7,762
+1,826
+31% +$147K ﹤0.01% 2539
2025
Q4 		$463K Sell
5,936
-640
-10% -$42.8K ﹤0.01% 2710
2025
Q3 		$399K Sell
6,576
-36
-0.5% -$1.4K ﹤0.01% 2842
2025
Q2 		$173K Buy
+6,612
New +$198K ﹤0.01% 3307

Other funds holding DRUG

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
AdvisorShares Investments
AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

RhumbLine Advisers's DRUG Position: Q3 2026 in Review

RhumbLine Advisers increased its Bright Minds Biosciences (DRUG) stake by 3.1% in Q3 2026, buying an estimated $18.9K and bringing the position to 9,001 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #2801.

RhumbLine Advisers first reported a position in DRUG in Q2 2025 and has held it in 6 quarters since. The position peaked at $613K in Q2 2026. 35 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

  • RhumbLine Advisers held 9,001 shares of Bright Minds Biosciences worth $448K as of Q3 2026.
  • RhumbLine Advisers bought 268 Bright Minds Biosciences shares in Q3 2026, an estimated $18.9K.
  • Bright Minds Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2801 holding.
  • RhumbLine Advisers first reported a position in Bright Minds Biosciences in Q2 2025 and has held it in 6 quarters since.
  • RhumbLine Advisers's Bright Minds Biosciences position peaked at $613K in Q2 2026.
  • 35 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.